The usefulness of a disease severity staging classification system for IPF in Japan: 20 years of experience from empirical evidence to randomized control trial enrollment

Respiratory Investigation

Volumn 53, Issue 1, 2015, Pages 7-12

  Homma, Sakae ^a   Sugino, Keishi ^a   Sakamoto, Susumu ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute exacerbation; Disease severity stage; Idiopathic pulmonary fibrosis; Randomized controlled trial practice; Survival

Indexed keywords

ACETYLCYSTEINE; CARBON MONOXIDE; OXYGEN; PIRFENIDONE; PYRIDONE DERIVATIVE;

DECISION MAKING; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG TOLERABILITY; FIBROSING ALVEOLITIS; HUMAN; INCIDENCE; JAPAN; JAPANESE (PEOPLE); LUNG FUNCTION; MAJOR CLINICAL STUDY; MEDICAL CARE; MONOTHERAPY; OXYGEN DESATURATION; OXYGEN SATURATION; PHASE 3 CLINICAL TRIAL; POSTMARKETING SURVEILLANCE; PULSE OXIMETRY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL; VITAL CAPACITY; CLASSIFICATION; EMPIRICAL RESEARCH; EVIDENCE BASED MEDICINE; IDIOPATHIC PULMONARY FIBROSIS; OXIMETRY; PATIENT SELECTION; SEVERITY OF ILLNESS INDEX; TIME;

ACETYLCYSTEINE; EMPIRICAL RESEARCH; EVIDENCE-BASED MEDICINE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; JAPAN; OXIMETRY; PATIENT SELECTION; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TIME FACTORS; VITAL CAPACITY;

EID: 84920376076     PISSN: 22125345     EISSN: 22125353     Source Type: Journal    
DOI: 10.1016/j.resinv.2014.08.003     Document Type: Review

References (21)

1. Zappala C.J., Latsi P.I., Nicholson A.G., et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2010, 35:830-836.
2. Flaherty K.R., Andrei A.C., Murray S., et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute walk test. Am J Respir Crit Care Med 2006, 174:803-809.
3. Collard H.R., King T.E., Bartelson B.B., et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003, 168:538-542.
4. King T.E., Safrin S., Starko K.M., et al. Analysis of efficacy endpoints in a controlled trial of interferon-gamma 1 b for idiopathic pulmonary fibrosis. Chest 2005, 127:171-177.
5. Japanese Respiratory Society[U+05F3]s Committee formulating diagnosis and treatment guideline for diffuse lung diseases. Clinical diagnostic and treatment guidance for idiopathic interstitial pneumonias. Tokyo, Nankodo; 2004.
6. Inoue Y, Azuma A, Ogura T, et al. All-case post-marketing surveillance (PMS) of pirfenidone in Japan: clinical characteristics, efficacy and safety profile in >1300 patients with idiopathic pulmonary fibrosis (IPF). 2013 ERS Annual Meeting, P3369, Barcelona.
7. Eaton T., Young P., Milne D., et al. Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2002, 165:277-304.
8. Chiba H, Natsuizaka M, Shiratori M, et al. Epidemiological survey of patients with idiopathic interstitial pneumonias using clinical personal records in Hokkaido. The annual report by study group of ministry of health and welfare for diffuse lung diseases; 2012. p 125-34.
9. Nathan S.D., Shlobin O.A., Weir N., et al. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest 2011, 140:221-229.
10. Kim D.S., Park J.H., Park B.K., et al. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J 2006, 27:143-150.
11. Sakamoto K., Taniguchi H., Kondoh Y., et al. Acute exacerbation of idiopathic pulmonary fibrosis as the initial presentation of the disease. Eur Respir Rev 2009, 18:129-132.
12. Nukiwa T, Abe T, Yaekashiwa M, et al. A revised clinical staging classification of idiopathic interstitial pneumonia. The annual report by study group of ministry of health and welfare for diffuse lung diseases; 1998. p. 36-41.
13. Kondoh Y., Taniguchi H., Katsuta T., et al. Risk factors of acute exacerbation of idiopathic pulmonary fibrosis. Sarcodosis Vasc Diffuse Lung Dis 2010, 27:103-110.
14. Taniguchi H., Ebina M., Kondoh Y., et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010, 35:821-829.
15. Azuma A., Taniguchi Y., Ogura T., et al. Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. Respir Res 2011, 12:143.
16. Nukiwa T. Evidence from Asian-Pacific respiratory medicine: clinical trials and ethnicity for personalized EGFR-TKI in NSCLC and pirfenidone in IPF. 18th Congress of the Asian Pacific Society of Respirology, Yokohama; 2013, P123.
17. Homma S., Azuma A., Taniguchi H., et al. Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis. Respirology 2012, 17:467-477.
18. Taniguchi H, Kataoka K, Kondoh Y, et al. A questionnaire survey for revision of disease severity criteria of idiopathic pulmonary fibrosis in Japan. The annual report by study group of ministry of health and welfare for diffuse lung diseases; 2010. p. 67-73.
19. Taniguchi H, Kataoka K, Kondoh Y, et al. Proposal for revised classification of disease severity of idiopathic pulmonary fibrosis in Japan. ERS annual meeting 2011, Abstract No. 2609.
20. Shah N.R., Noble P., Jackson R.M., et al. A critical assessment of treatment options for idiopathic pulmonary fibrosis. Sarcodosis Vasc Diffuse Lung Dis 2005, 22:167-174.
21. Sugino K., Ito T., Muramatsu T., et al. Comparison of the clinical features of idiopathic pulmonary fibrosis in Japan and the USA, based on disease severity. Nihon Kokyuki Gakkai Zasshi 2010, 48:892-897.